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SYNOPSIS  
Novel imaging techniques are allowing hepatologists to investigate the structural and functional 
neuropathology of hepatic encephalopathy (HE) in greater detail but only limited techniques are 
applicable to the clinic. Computed tomography and magnetic resonance imaging (MRI) can rule out 
other diagnoses and in the case of MRI, give certain key diagnostic features in widely available 
sequences. While increased brain water content is a hallmark of HE, the localisation of low-grade 
cerebral edema, the extent of regional swelling or atrophy and the different functional characteristics 
of affected brain regions continue to be debated.  More specialised volumetric, diffusion-tensor, 
magnetization transfer, functional magnetic resonance imaging and magnetic resonance 
spectroscopy, in conjunction with positron emission tomography continue to enrich the investigative 
findings in HE. Nevertheless an internationally accepted diagnostic framework that includes an 
objective imaging test to replace or augment psychometry remains elusive. Quantitative MRI is likely 
to be the best candidate to become such a test and the utility of MR and nuclear medical techniques 
to the clinic and results from recent research are described in this article. 
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1. Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric disturbance affecting patients with acute liver 
failure (ALF), cirrhosis or non-cirrhotic portosystemic bypass (1). The clinical spectrum of HE extends 
from mild cognitive impairment, to coma and death (2). The majority of cases involve patients with 
minimal HE (MHE), which has been associated with an impaired ability to drive automobiles safely, 
reduced health-related quality of life and increased risk of hospitalization due to overt HE (3-5).  
 
The disease process is multifactorial, with hyper-ammonaemia, gut-derived toxins, short and medium 
chain fatty acids, cerebral manganese deposition and relative deficiencies in circulating amino acids 
with consequent neurotransmitter imbalance commonly implicated. There is consensus that ammonia 
is central to the pathogenesis (6). Varying degrees of cerebral edema may result from the uptake of 
excess ammonia into astrocytes, with subsequent conversion to glutamine, which acts as a cerebral 
osmolyte, mitochondrial toxin and instigator of neurotransmitter instability (7-11). 
 
Currently, the diagnosis of HE lacks standardization, particularly in MHE, which requires 
neuropsychiatric testing to detect cognitive impairment. Psychometric test results can be dependent 
on the patient’s age, educational status, emotional affect and linguistic abilities. Evaluation varies 
between countries while in some forms of testing, considerable expertise and facilities to conduct an 
assessment are required (12). This perceived diagnostic difficulty leads to under recognition of this 
important clinical problem. Even when the presentation of HE is clinically overt, the grading and 
assessment of longitudinal change is subjective among clinicians, and is also prone to disagreement 
or even misdiagnosis (12).  
 
The cerebral insults secondary to hepatocellular failure or portosystemic shunting result in structural 
and functional abnormalities in the brain, which imaging may detect and quantify. Suitable modalities 
include magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), computed 
tomography (CT) in conjunction with positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) (Table 1 and Box 1). These imaging techniques may allow the 
development of tools for the objective, reproducible and non-invasive diagnosis and monitoring of HE. 
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While stand-alone computed tomography (CT) is useful for determining gross structural lesions such 
as cerebral edema in ALF or other pathologies in patients with CLD, it is limited as a diagnostic and 
longitudinal research tool, owing to poor sensitivity and repeated exposure to ionizing radiation. MRI 
and PET/SPECT will thus be the focus for this article with particular focus on patients with HE 
secondary to cirrhosis, where most possibility for diagnostic doubt or pathophysiological disagreement 
exists. 
 
2. Magnetic Resonance Imaging 
MRI is currently the most frequently utilized imaging tool in HE research studies and even standard 
clinical sequences can give information supporting a diagnosis of HE. A clinical set of sequences 
when requesting an “MR Brain” study would usually consist of T1- and T2-weighted sequences as 
standard and a selection of more advanced T2-weighted sequences such as Fluid Attenuated 
Inversion Recovery (FLAIR) or Diffusion-Weighted Imaging (DWI).  
 
2.1 T1-weighted MRI 
Bilateral and symmetric hyper-intensity of the basal ganglia, using T1-weighted MRI sequences in 
patients with cirrhosis is an observation with some clinical utility (Figure 1) (14-17). It has been 
postulated that excess circulating manganese is the cause of such hyperintensity, due to reduced 
hepatobiliary excretion as a result of liver failure, and subsequent deposition in the basal ganglia 
where blood flux is high (18,19). This theory has been corroborated by the correlation between blood 
and cerebrospinal fluid manganese levels with T1-weighted hyperintensity; and also the normalization 
of basal ganglia hyperintensity and blood levels of manganese after liver transplantation (20-22).  
 
However, the results of studies investigating the relationship between manganese-related pallidal 
hyperintensity and psychometric performance in HE are conflicting (23,24). It is therefore unclear 
whether T1-weighted hyperintensity represents a manifestation of HE, or if it is an occurrence 
secondary to cirrhosis, cholestasis and/or porto-systemic shunting (25,26).  The preferential 
deposition of manganese in the basal ganglia has been suggested to be an explanation for the 
Parkinsonian-like symptoms, which can arise as a result of HE (27). So while a useful adjunct this 
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lack of correlation with grades of HE makes a single T1-weighted exam insufficient in MR Brain in 
patients with cirrhosis. 
 
2.2 T2-weighted MRI: Fast FLAIR Imaging 
Fast FLAIR (Fluid Attenuated Inversion Recovery) T2-weighted imaging represents a MRI sequence 
that has been shown to be sensitive for the detection of diffuse high intensity white matter lesions 
(WMLs) (28,29). WMLs may develop secondary to cerebrovascular small-vessel disease, which 
neuropathologically, are a combination of reversible edema and irreversible neuronal damage. (30). 
Minguez and colleagues noted WMLs were found to be reduced in volume and number after 
treatment with neomycin and/or branched-chain amino acids in conjunction with improved 
psychometric performance (31). To further investigate this observation, the same investigators 
compared WML volumes in patients with impaired cognition, pre- and post-liver transplantation (32). A 
significant reduction in WML volume was detected after liver transplantation (Figure 2), as well as a 
strong negative correlation between fast FLAIR T2-weighted lesion load and psychometric score. 
Rovira and colleagues, and Cordoba and colleagues, measured high-signal intensity, along the 
corticospinal tract on fast FLAIR T2-weighted images in patients with chronic liver disease, with 
subsequent signal normalization after liver transplantation. (33,34).  
 
2.3 T2-weighted MRI: Diffusion Weighted Imaging  
Diffusion-Weighted MRI (DW-MRI) is a commonly available sequence often used in assessing 
neurovascular disease which assesses changes in the motion of water molecules, by defining the 
chemical interaction between water and cellular barriers (35). The diffusivity of water molecules can 
be quantified by calculating the apparent diffusion coefficient (ADC) and can distinguish between 
vasogenic (interstitial) and cytotoxic edema (36,37).   
 
Several studies have consistently demonstrated a link between increased cerebral ADC 
(demonstrating interstitial edema) and patients with either MHE or overt HE; the degree of brain water 
diffusivity also correlating with grade of HE (37-40).  DW-MRI studies have countered the traditional 
astrocytic swelling hypothesis, suggesting increased ADC values relate to purely extracellular water 
accumulation in low-grade cerebral edema, secondary to chronic HE (37,41-43). Theories that explain 
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this phenomenon include hyperammonemia-induced increased blood-brain barrier permeability and 
reduced glial fibrilliary acidic protein (GFAP) expression, a protein that regulates astrocytic 
permeability; reduced membranous GFAP in astrocytes has been previously linked increased 
diffusivity in the extracellular space (44-46).  Discrepancies in studies where ADCs have been raised 
or lowered in clinically defined HE may be related to the onset of disease. Lower ADC values have 
been noted in patients with HE, secondary to ALF (and cytotoxic edema), whereas higher 
periventricular white matter and basal ganglia ADC in patients with CHE have been suggested to 
support a finding of interstitial edema (47). 
 
Detection of water diffusion has improved in recent years with the development of diffusion tensor 
MRI (DT-MRI), a technique that provides detailed information on brain tissue structure. Fractional 
anisotropy (FA, where the fractional free or bound water component is estimated) maps can be 
assimilated to perform “tractography”, a method of determining underlying brain anatomy and where 
edema is localised (48). Kumar and colleagues demonstrated increased mean diffusivity in the 
internal capsule and cortical gray and white matter of HE patients, but differential patterns of 
correlation between mean diffusivity and fractional anisotropy in the corpus collusum suggested that 
interstitial edema was the primary HE correlate in this study of 14 low-grade HE patients. While DWI 
is often used in clinical scanners, and we would recommend using T1-weighted and FLAIR/DWI T2-
weighted sequences, the statistical requirements of DTI make it currently unsuitable for standard 
clinical use.  
 
2.4 Volumetric MRI 
Shah and colleagues correlated quantitative T1 mapping of cerebral water content in the putamen, 
globus pallidus and occipital white matter with severity of HE (13). This was one of the first direct and 
quantitative measurements of increased regional cerebral water content with more severe grades of 
HE, but the imaging technique is highly specialised. Cerebral edema that occurs as a result of ALF 
can be routinely viewed using MRI (49), but is often low grade and is hence undetectable by 
radiologists in chronic HE. The question arises of whether a simple measure of total brain volume 
(BV) would be useful. Recent developments in software packages for brain volumetry allow small 
(<1% total BV) changes in brain size in HE to be quantitated, allowing precise measurements of BV 
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(50) on relatively standard T1-weighted MR sequences (51-55). Single time-point determination of 
brain volume is considerably less accurate than when BV change is determined longitudinally, owing 
to the ability to co-register (align) images using the theoretically unchanged skull surface, thus 
allowing more robust determination of CSF and gray and white matter densities (50,56). Further 
structural information can be determined using voxel-based morphometry (VBM) where regional 
contribution to brain volume change can be calculated; this has been applied in many 
neuropathological scenarios (57). 
 
A pilot study conducted by Patel and colleagues, was the first to utilize co-registered MRI techniques 
to determine changes in BV in chronic liver disease (58). This small scale investigation focused on six 
patients with MHE, and three patients who had been diagnosed with overt HE. The authors concluded 
that in patients treated with lactulose brain volume fell, in association with improved psychometric 
performance.  
 
In contrast patients with HE often have risk factors for cerebral atrophy (such as age, alcohol abuse 
and possibly cirrhosis itself) and these effects couldalso contribute to neuropsychological impairment 
and apposite structural brain changes. Garcia-Martinez and colleagues investigated cognitive 
function, cerebral magnetic resonance spectroscopy and BV post-liver transplantation (59). Post-
transplantation, BV was reduced in patients with prior HE, correlating with worse neuropsychiatric 
score in this group. This study, suggests that brain atrophy accrued prior to liver transplantation, but 
masked by low grade edema, may also play a role in cognitive dysfunction post-transplantation. 
Further evidence of the contribution of atrophy in patients with hepatic encephalopathy has recently 
emerged with the identification areas of atrophy throughout the cortex and white matter quantitated by 
VBM and correlating with the severity of encephalopathy (60). A lack of corroborative MR 
spectroscopy or more advanced water localisation sequences could not add further mechanistic data 
to this interesting observation, which requires validation from other groups. 
 
2.5 Magnetization Transfer Imaging  
Magnetization transfer imaging (MTI) improves image contrast as a consequence of the magnetic 
properties of free and bound protons (61). Free protons are present in water molecules, whereas 
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bound protons are fixed to macromolecules, such as proteins, lipids, carbohydrates and nucleic acids 
(62). Magnetization transfer between bound and free protons reduces the signal intensity observed in 
the resultant MR image (17,25). MTI also allows for the magnetic transfer ratio (MTR) to be quantified, 
which ultimately reflects brain parenchymal changes: a low MTR indicates neuronal damage as well 
as an increase in water content or membrane permeability (17,63).  
 
Lower MTRs have been demonstrated in patients with HE, including a cohort who developed MHE 
secondary to extra-hepatic portal vein obstruction (64-66). A study by Cordoba and colleagues 
verified this by concluding MTR normalisation post-transplantation reflected the correction of low-
grade cerebral edema in patients with MHE, and that the basal ganglia and white matter are initial 
targets for water accumulation (67). A study by Miese and colleagues that utilized both MTI and DW-
MRI to investigate cerebral edema in HE, found that both reduced MTR and raised ADC were 
correlated with HE grade in non-alcoholic patients (40). However, in patients continuing to drink to 
alcohol to excess, no such correlation was established, suggesting chronic alcohol mis-use may 
independently cause cerebral oxidative damage in this group,  although as has been noted above, the 
effect of atrophy on these measurements may be underestimated (68).  
 
2.6 Functional MRI  
Functional MRI (fMRI) measures changes in deoxyhaemoglobin concentration (a substance with 
paramagnetic properties, relative to tissue) that occurs as a result of the rise in blood oxygenation 
during neuronal activity (69). The subsequent blood oxygen level dependent (BOLD) contrast 
highlights areas of activity in the brain.  
 
fMRI has the benefit of being a non-invasive and safe investigatory tool in low grade HE (as these 
patients can follow instructions in the scanner), that is particularly useful in longitudinal studies as no 
radioactive marker injections are required (35). Zafiris and colleagues demonstrated that MHE is 
associated with impaired coupling between visual judgment areas (70). A study conducted by Zhang 
and colleagues compared brain fMRI data in 14 patients with cirrhosis and 14 healthy volunteers (71). 
An incongruous word reading task and incongruous color-naming task (testing for attention and 
interference) highlighted various cerebral areas on fMRI: there was greater activation of the bilateral 
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parietal and prefrontal cortices in the patients with cirrhosis (72). In a separate study, Zhang and 
colleagues concluded there was reduced functional connectivity in the right middle frontal gyrus and 
left posterior cingulate cortex, (part of the default-mode network [DMN)).. This highly interconnected, 
metabolically active and well described area of the brain is vital for the preservation of attention and is 
worthy of further study into whether this abnormal activation is related to hyperammonemia or low-
grade cerebral edema (73-75). 
 
2.7 Magnetic Resonance Spectroscopy 
MRS has been utilised in HE investigations since the 1980s, although it has been more widely used in 
recent times as a consequence of improved sequence development and higher field strength to 
resolve metabolite signals. MRS also allows for the investigation of HE at the molecular level, by 
studying cerebral tissue in vivo in whole-body clinical magnets (typically at 1.5-3.0T) (76).  
 
Various nuclei can be used to determine metabolite changes in HE, the most common clinically-used 
being proton (
1
H) and 31-phosphorus (
31
P) MRS. 
1
H MRS allows for the quantification of metabolites 
such as choline (Cho), creatine (Cr), N-acetyl aspartate (NAA), glutamine (Gln) and glutamate (Glu) or 
the unresolved combination (Glx), as well as osmolytes such as myo-inositol (mI) and taurine. 
31
P MR 
spectra allow definition of phosphomonoester (PME), inorganic phosphate (Pi), phosphodiester 
(PDE), phosphocreatine, γATP, αATP and βATP resonances (or also more correctly termed 
nucleoside triphosphate resonances [NTP], as they also contain contributions from cytosine 
triphosphate, guanosine triphosphate and uridine triphosphate, in addition to the overwhelming 
proportion from adenosine triphosphate, [ATP]) (77). These resonances provide information on cell 
membrane turnover with cell membrane precursors measured in the PME resonance and cell 
membrane degradation products measured in the PDE resonance, while information on high energy 
phosphate metabolism and intracellular pH is available from the Pi, PCr and NTP resonances (78-80). 
Ammonia is not detected by MRS due to rapid interchange with water (81).  
 
The characteristic spectral appearance of HE on in vivo 
1
H MRS adds further evidence to the 
astrocyte swelling hypothesis demonstrated by a reduction in intracellular mI and Cho, and a 
concurrent increase in Gln and Glu (Figure 3) (77,82). Furthermore, these characteristic metabolic 
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changes have been shown to correlate with psychometric performance (23). This suggests that cells 
expel osmolytes, such as taurine, mI and Gln, in the face of an osmotic water load. In vivo 
1
H MRS 
allows the degree of intracellular osmolyte homeostasis to be detected and monitored sequentially 
and to give an indirect indication of cell swelling in a non-invasive way. The technique is also open to 
following response to therapeutic intervention. Recent sequence development using 2-dimensional 
spectroscopy allows improved resolution of 1-dimensional 
1
H MRS and resolution of glutamine and 
glutamate (Figure 4) (83). 
 
The interpretation of 
31
P MRS is complex in vivo, since many of the resonances are multi-component 
and are not easily separated into their constituents at clinically-used magnetic field strengths. Overall, 
however, changes do appear to reflect alterations in bioenergetic pathways, and glucose utilisation 
(since sugar phosphates also contribute to both the PME and PDE resonances), as well as giving an 
indication of phospholipid membrane synthesis and degradation and of cell membrane fluidity (77,84). 
Consensus on 
31
P MRS studies has been hampered by small study sample sizes and inconsistencies 
in MRS protocols between centers (35). Studies conducted by Taylor-Robinson and colleagues have 
demonstrated reductions in the PME/ βATP and PDE/ βATP which correlate with reduced choline, as 
verified by parallel 
1
H MRS on the same subjects (77,84,85). These changes were thought to 
represent reduced glucose utilisation in HE, as components of the glycolytic pathway contribute to the 
31
P MRS spectrum in vivo. However, a change in membrane fluidity is equally possible. 
1
H in vivo 
MRS is more likely to be developed for clinical use but normal ranges and diagnostic thresholds for 
key metabolites are not yet agreed. 
 
3. Nuclear medicine: Positron Emission Tomography and Single Photon Emission Computed 
Tomography  
PET involves the measurement of the concentration of positron emitting radioisotopes from the body. 
Co-registered CT or MR tomographic imaging provides structural information, while, depending on the 
radioligand used, functional data are available in the form of glucose and oxygen metabolism, blood 
flow, amino acid metabolism and rates of amino acid incorporation into proteins, acid-base balance 
and membrane transport (86). Positron-emitting radionuclides that are used in PET include: 
11
C, 
18
F, 
15
O, and 
13
N (87). 
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Lockwood and colleagues have used 
18
F-fluorodeoxyglucose (FDG) PET to investigate functional 
changes in chronic HE (88,89). They demonstrated a reduction in glucose metabolism in the anterior 
cingulate gyrus, which may reflect the attention deficit found in many HE patients on 
neuropsychometric testing and in fMRI studies. Alterations in cerebral blood flow (CBF) have also 
been established using FDG PET and 
15
O PET, where poor neuropsychiatric performance correlated 
with reduced blood flow in all cortical areas; temporal lobe CBF was found to be most discriminatory 
between HE patients and healthy volunteers (88).  
 
Brain imaging with 
13
N-ammonia, has been used to assess cerebral ammonia metabolism in (i) 
healthy subjects, (ii) subjects with mild liver disease, but with no evidence of cirrhosis, (iii) subjects 
with cirrhosis with and without HE, and (iv) subjects with malignant neoplasms with metastases in the 
liver (90-94). However, the results of these studies are somewhat conflicting, particularly with respect 
to interpretation of blood-brain barrier (BBB) permeability in HE. This is probably owing to differences 
between research groups in the tracer kinetic modeling approach used to determine parameters of 
cerebral ammonia metabolism quantitatively. Different expert opinions exist over which conclusions 
should be drawn out of conflicting results in PET studies of ammonia metabolism and BBB 
permeability. Some proponents suggest that further studies, including larger numbers of patients and 
using standardized analysis techniques are necessary, in order to provide consensus and easy 
methodology to clarify the relationship between BBB permeability and ammonia toxicity (95).  
 
Changes in different neurotransmission systems have been demonstrated in HE patients using 
radiotracer methods. Increased benzodiazepine receptor binding, decreased dopamine receptor 
binding and decreased binding to serotonin transporters have been shown (Figure 5) (96). These 
changes correspond to symptoms observed in HE (depression of neuropsychological function and 
extrapyramidal symptoms) and suggest possible targets for treatment (97-99). Studies of neuronal 
activity have been used to shed light on the pathophysiology of HE, while imaging of a potentially 
crucial process in HE, neuroinflammation, using the radioligand C-11-PK11195 to detect peripheral 
benzodiazepine receptors (PTBR), which are present on a number of cell types, including activated 
microglial cells, is gaining increased attention (100-102).  
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Molecular imaging using SPECT requires a molecular marker that is labelled with a radionuclide, 
which results in the emission of gamma ray photons or high-energy X-ray photons (103). Cerebral 
blood flow is most commonly assessed by using 
99
Tc or 
133
Xe radioactive tracers. Despite SPECT 
being more readily available and cheaper than PET, the latter is preferred in functional imaging 
studies due to its superior spatial and temporal resolution (86). Previous studies have demonstrated 
increased cerebral blood flow in the basal ganglia in patients with MHE, suggesting increased 
ammonia delivery to these areas, resulting in astrocytic dysfunction and cognitive alterations 
(104,105). This is in agreement with a 
1
H MRS study by Taylor-Robinson and colleagues that 
demonstrated Glx concentration was highest in the basal ganglia (82). However, SPECT studies that 
have investigated HE have been thwarted by small study sizes, limiting the conclusions that can 
presently be drawn from the use of this functional imaging tool. 
   
4 Summary 
In a patient with liver disease and neurological impairment, a CT scan and/or preferably, MRI of the 
brain can rule out other diagnoses and provide some corroborative evidence of HE. More research-
based modalities such as MRT, DTI, MRS, PET and SPECT have provided valuable insight into the 
pathogenesis of HE, but have not been transformed into widely available diagnostic tools. Prior to this 
transformation, there must be consensus with regards to uniformity of study protocols, imaging 
sequences and analysis methodologies, both in MRI/MRS and in PET/SPECT, where promising 
functional data are emerging. In the future, a quantitative MR technique is most likely to give 
objective, reproducible and longitudinal diagnostic information in this common but under recognised 
complication of liver disease. 
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Imaging 
technique 
Availability Findings in Hepatic Encephalopathy Recommended in 
the clinic 
CT Brain Standard Cerebral edema in ALF 
Rules out some common differential 
diagnoses 
Yes 
 
MRI brain 
   
T1-weighted Standard Basal ganglia hypersensitivity  
(not HE specific) 
Cerebral oedema in ALF  
Quantitative brain volume by 
research statistical methods 
 
Yes (not in ALF) 
T2-weighted 
FLAIR 
 
 
DWI 
 
Standard 
 
 
Standard 
 
White matter lesions in cases of low 
grade HE 
 
High ADC in CHE 
Low ADC in ALF 
 
Yes (not in ALF) 
Diffusion tensor 
imaging 
 
Research  
 
Increased mean diffusivity in 
corticospinal tracts 
No 
Magnetisation 
Transfer 
 
Available in 
specialist centres 
Low MTR in white matter No 
1H MR 
Spectroscopy 
Available in 
specialist centres 
High Glx (glutamine/glutamate) 
Low myoinositol and choline in basal 
ganglia and frontal white matter 
No 
Functional MRI Research Deactivation of the default mode 
network including the anterior 
cingulate 
 
Nuclear 
medicine 
 
   
PET Research in HE Reduced glucose uptake in the 
anterior cingulate 
No 
SPECT Research in HE Increased blood flow to the basal 
ganglia 
No 
Table 1: Approach to different imaging modalities in HE in clinical and investigative use 
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 CT Brain can demonstrate edema in ALF and assists in the differential diagnosis of 
neurological impairment in cirrhosis 
 MR Brain is not recommended routinely in ALF but can assist in the diagnosis of HE in 
cirrhosis where it is the preferred method of brain imaging 
 Quantification of cerebral metabolites or brain water is possible but not yet widely used 
diagnostically 
 PET/SPECT are powerful but expensive research tools 
 
Box 1: Clinical and research imaging techniques applied in the diagnosis of hepatic encephalopathy 
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Figure 1: T1-weighted magnetic resonance image of the brain of a patient with cirrhosis. The arrow 
demonstrates the area of pallidal hyperintensity. Reproduced from Córdoba J, et al.  
1
H magnetic 
resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002;17(4):415. With 
permission from Springer Inc. 
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Figure 2: A. Baseline fast-FLAIR MRI image of a hepatitis C patients prior to liver transplantation. 
Focal lesions can be visualized in the subcortical white matter (arrows). B. Same MRI study 6 months 
post-liver transplant in the same patient; there is a noticeable decrease in the size of focal white 
matter lesions. Reproduced from Rovira A, et al. Decreased white matter lesion volume and improved 
cognitive function after liver transplantation. Hepatology 2007;46(5):1485. With permission from John 
Wiley and Sons Inc. 
 
 
Figure 3: 
1
H MR spectra from the basal ganglia of a patient with chronic hepatic encephalopathy and 
healthy volunteer, demonstrating decreased choline/creatine ratio and increased glutamate/glutamine 
resonance in the CHE patient. Cho: choline; Cr: creatine; Glx: glutamine/glutamate; NAA: N-acetyl 
aspartate. Reproduced from Taylor-Robinson SD, et al. Regional variations in cerebral proton 
spectroscopy in patients with chronic hepatic encephalopathy. Metab Brain Dis. 1994 Dec;9(4):347-59 
With permission from Springer Inc. 
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Figure 4: The 2D-COSY spectrum from the occipital lobe of a 51-year-old patient with minimal hepatic 
encephalopathy. Cr: creatine; Ch: choline; Glx: glutamate/glutamine; NAA: N-acetyl aspartate; Asp: 
aspartate; PE: phosphoethanolamine; PCh: phosphocholine; mI: myoinositol; Tau: taurine; ThrLac: 
overlapping cross peaks of threonine and lactate; GABA: gaba-aminobutyric acid; mICh: overlapping 
cross peaks of myo-inositol and choline; MM: macromolecules. Reproduced from: Singhal A et al. 
Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological 
correlates in vivo. Journal of magnetic resonance imaging 2010;32(1):35. With permission from John 
Wiley and Sons Inc. 
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Fi Figure 5: Analyses of benzodiazepine binding in patients with hepatic failure (top row), control 
(middle row), and voxel-by-voxel comparison of between-group differences (bottom row). The 
greatest changes in distribution volume of flumazenil was seen in the cerebellum. Reproduced from 
MacDonald GA, et al. Cerebral benzodiazepine receptor binding in vivo in patients with recurrent 
hepatic encephalopathy. Hepatology 1997;26(2):277. With permission from John Wiley and Sons Inc. 
gure 5 
 
 
